



Zorginstituut Nederland

Experiences with ADAPTSMART and MAPPs

Personal Reflection from a HTA perspective

W. Goettsch^{1,2}

1. National Healthcare Institute, Diemen, the Netherlands
2. Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands



ADAPTSMART and MAPPs (five years later)

- Involved in early discussions through the NEWDIGS initiative
- Participated in some of the early dialogues as part of the EMA pilot
- Become part as one of the four HTA partners in ADAPTSMART
 - Effectively it was mostly input from NICE
 - And some input of ZIN



Early promises and thoughts

- Designing a new approach of regulatory access, HTA, reimbursement and pricing for a specific type of pharmaceuticals
- Should be based on a close collaboration of different stakeholders such as regulators, patients, payers, industry, HTA and clinicians
- Should ensure a link between between national approaches and international collaborations between EUnetHTA and EMA



But now....

- Acceptance of MAPPs under HTA bodies is low
- Feeling that the discussion has been largely industry-driven
- No real case studies/pilots in which there was involvement from all stakeholders
- Confusion on the distinction between MAPPs and PRIME
- Is MAPPs deceased?